Farokhzad and colleagues have considerable expertise with bench - to - bedside translation of nanotechnologies for medical applications, and foundational work done in part
by his team has led to the development and first in human testing of a targeted
nanoparticle capable of controlling drug release for treatment of cancers, and the first in human testing of a targeted
nanoparticle vaccine capable of orchestrating an immune response to
facilitate smoking cessation and relapse prevention.